Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

When I first entered the clinical research industry more than 20 years ago, trials were focused mainly on recruitment goals and data collection, with less attention to the challenges faced by research ...

Make no mistake, innovation in diabetes care is critical. Diabetes never takes a break. People with diabetes manage their condition on their own, 365 days a year – making multiple therapy decisions ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval of lecanemab. This particular therapy is a monoclonal antibody treatment for use among patient populations with mild ...

The impact of AI/data-driven drug discovery is evolving rapidly in life sciences. Harnessing the beneficial potential of this technology, however, requires its ...

Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...

Chiesi Group has appointed Laura Vergani as SVP of Global Communications Chiesi Group has announced that Laura Vergani has joined as Senior Vice President of Global Communications & Public Affairs.

Environmental sustainability is one of the great challenges of our age and healthcare companies, systems and organisations are adapting their operating practices. This dynamic environment has prompted ...

New treatment option for patients with newly diagnosed multiple myeloma The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with bortezomib, ...

Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and ...